A multi-institutional review of outcomes in biopsy-proven chronic invasive fungal sinusitis.
chronic disease
fungal sinusitis
invasive fungal sinusitis
paranasal sinus disease
sinusitis
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
10
08
2019
revised:
16
01
2020
accepted:
21
01
2020
pubmed:
14
4
2020
medline:
12
8
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
Chronic invasive fungal sinusitis (CIFS) is a rare, life-threatening infection of the nose and sinuses. This study aims to identify factors that impact survival in 1 of the largest cohorts to date. Pathology records were reviewed for biopsy-proven CIFS from 3 tertiary academic institutions from 1995 to 2016. Variables were analyzed using log-rank survival analysis. Univariate Cox regression was performed at 1 and 12 months. Thirty-eight patients were included. Hematologic malignancy and diabetes were the most common underlying diseases (32% each). Aspergillus was the most common fungus (63%). Greater than 75% of the patients had an absolute neutrophil count (ANC) >1000 at the time of diagnosis. Overall survival at 1, 6, and 12 months was 89%, 68%, and 48%, respectively. In univariate analysis, factors associated with worse survival included: ANC <500 at 12 months (hazard ratio [HR] 4.8; p = 0.01), ANC <1000 at 12 months (HR 5.8; p = 0.001), and recent chemotherapy (HR 4; p = 0.01). The following factor was associated with improved survival in univariate analysis: ANC as a linear variable in the entire cohort (HR 0.7; p = 0.005). We present a multi-institutional case-series of CIFS and long-term follow-up. ANC <1000 at time of diagnosis and recent chemotherapy (within 1 month of diagnosis) are associated with poorer survival, whereas a rising ANC >1000 is associated with improved survival at 12 months. Further prospective studies are needed to further define factors that affect outcomes.
Sections du résumé
BACKGROUND
Chronic invasive fungal sinusitis (CIFS) is a rare, life-threatening infection of the nose and sinuses. This study aims to identify factors that impact survival in 1 of the largest cohorts to date.
METHODS
Pathology records were reviewed for biopsy-proven CIFS from 3 tertiary academic institutions from 1995 to 2016. Variables were analyzed using log-rank survival analysis. Univariate Cox regression was performed at 1 and 12 months.
RESULTS
Thirty-eight patients were included. Hematologic malignancy and diabetes were the most common underlying diseases (32% each). Aspergillus was the most common fungus (63%). Greater than 75% of the patients had an absolute neutrophil count (ANC) >1000 at the time of diagnosis. Overall survival at 1, 6, and 12 months was 89%, 68%, and 48%, respectively. In univariate analysis, factors associated with worse survival included: ANC <500 at 12 months (hazard ratio [HR] 4.8; p = 0.01), ANC <1000 at 12 months (HR 5.8; p = 0.001), and recent chemotherapy (HR 4; p = 0.01). The following factor was associated with improved survival in univariate analysis: ANC as a linear variable in the entire cohort (HR 0.7; p = 0.005).
CONCLUSION
We present a multi-institutional case-series of CIFS and long-term follow-up. ANC <1000 at time of diagnosis and recent chemotherapy (within 1 month of diagnosis) are associated with poorer survival, whereas a rising ANC >1000 is associated with improved survival at 12 months. Further prospective studies are needed to further define factors that affect outcomes.
Substances chimiques
Antifungal Agents
0
Types de publication
Case Reports
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
738-747Informations de copyright
© 2020 ARS-AAOA, LLC.
Références
Chakrabarti A, Denning D, Ferguson B, et al. Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope. 2009;119:1809-1818.
D'Anza B, Stokken J, Greene JS, Kennedy T, Woodard TD, Sindwani R. Chronic invasive fungal sinusitis: characterization and shift in management of a rare disease. Int Forum Allergy Rhinol. 2016;6:1294-1300.
Pagella F, De Barnardi F, Gasperina DD, et al. Invasive fungal rhinosinusitis in adult patients: our experience in diagnosis and management. J Craniomaxillofac Surg. 2016;44:512-520.
Parikh SL, Venkatraman G, DelGaudio J. Invasive fungal sinusitis: a 15-year review from a single institution. Am J Rhinol. 2004;18:75-81.
Sharif MS, Ali S, Nisar H. Frequency of granulomatous invasive fungal sinusitis in patients with clinical suspicion of chronic fungal rhinosinusitis. Cureus. 2019;11:1-5.
Li Y, Li Y, Li P, et al. Diagnosis and endoscopic surgery of chronic invasive fungal rhinosinusitis. Am J Rhinol Allergy. 2009;23:622-625.
Stringer SP, Ryan MW. Chronic invasive fungal rhinosinusitis. Otolaryngol Clin North Am. 2000;3:375-387.
Pestana J, Carmo A, Ribeiro J, et al. Chronic invasive rhinosinusitis by Conidiobolus coronatus, an emerging microorganism. J Mycol Med. 2019;29:67-70.
Richter AI, Gallagher K. Chronic invasive fungal sinusitis causing a pathologic Le Fort 1 fracture in an immunocompetent patient. Ear Nose Throat J. 2016;95:E1-E3.
Milroy CM, Blandshard JD, Lucas S, Michaels L. Aspergillosis of the nose and paranasal sinuses. J Clin Pathol. 1989;42:123-127.
McGill TJ, Simpson G, Healy GB. Fulminant aspergillous of the nose and paranasal sinuses, a new clinical entity. Laryngoscope. 1980;90:748-754.
Wang T, Zhang L, Hu C, et al. Clinical features of chronic invasive fungal rhinosinusitis in 16 cases. Ear, Nose, Throat J. 2019;1-6.
deShazo RD, O'Brien M, Chapin K, et al. A new classification and diagnostic criteria for invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg. 1997;123:1181-1188.
deShazo RD. Syndromes of invasive fungal sinusitis. Med Mycol. 2009;47(Suppl 1):S309-S314.
Paknezhad H, Borchard N, Charville G, et al. Evidence for a ‘preinvasive’ variant of fungal sinusitis: tissue invasion without angioinvasion. World J Otorhinolaryngol Head Neck Surg. 2017;3:37-43.
Edelmayer L, Ito C, Lee W, et al. Conversion of chronic invasive fungal sinusitis from allergic fungal sinusitis in immunocompetence. Laryngoscope. 2019;129:2447-2450.
Wandell GM, Miller CM, Rathor A, et al. A multi-institutional review of outcomes in biopsy-proven acute invasive fungal sinusitis. Int Forum Allergy Rhinol. 2018;8:1459-1468.
Turner JH, Soudry E, Nayak JV, Hwang PH. Survival outcomes in acute invasive fungal sinusitis: a systematic review and quantitative synthesis of published evidence. Laryngoscope. 2013;123:1112-1118.
Payne SJ, Mitzner R, Kunchala S, Roland L, McGinn JD. Acute invasive fungal rhinosinusitis: a 15-year experience with 41 patients. Otolaryngol Head Neck Surg. 2016;154:759-764.
DelGaudio JM, Clemson LA. An early detection protocol for invasive fungal sinusitis in neutropenic patients successfully reduces extent of disease at presentation and long-term morbidity. Laryngoscope. 2009;119:180-183.
ZunigaMG, Turner JH. Treatment outcomes in acute invasive fungal rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2014;22:242-248.
Kennedy CA, Adams GL, Neglia JP, Giebink GS. Impact of surgical treatment on paranasal fungal infections in bone marrow transplant patients. Otolaryngol Head Neck Surg. 1997;116:610-616.